Industry News

Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.

Please click here to submit your news.

Reuters Television Report features NanoLogix Biotechnology and University of Texas Health Science Center Clinical Trial

NanoLogix, an innovator in the accelerated detection and identification of live-cell microorganisms, announced today Reuters Television has featured the NanoLogix rapid diagnostic technology in its global business coverage. Produced by Rob Muir, the report from Reuters features an interview with NanoLogix CEO Bret Barnhizer while the company was exhibiting at the American Society for Microbiology BioDefense and Emerging Diseases Research Meeting and Exhibition held in Washington, DC (February 7-9, 2011). The report includes an additional interview with Dr. Jonathan Faro of the University of Texas Health Science Center- Houston. Dr. Faro is currently leading a 300 patient trial utilizing NanoLogix BNP/BNF/Quick-Test technologies for rapid detection of Group B Streptococcus (GBS).

Group B Strep is one of the leading health threats for newborns. Current methods for detection and identification take 48 to 72+ hours for results. The new technology from NanoLogix enables detection, identification, and determination of antibiotic sensitivity in 6 hours or less. NanoLogix will return to Washington DC April 19-21, 2011 for the Food Safety Summit, where the company's technology will be on exhibit.

Post a Comment

Previous Post Next Post

Contact Form